A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

OBJECTIVES: A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of thalidomide in persistent or recurrent endometrial cancer refractory to cytotoxic chemotherapy, and to correlate angiogenesis biomarker expression with clinical outcome. METHODS: Consenting patients...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: McMeekin, D. Scott, Sill, Michael W., Benbrook, Doris, Darcy, Kathleen M., Stearns-Kurosawa, Deborah J., Eaton, Lynne, Yamada, S. Diane
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2007
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1931832/
https://ncbi.nlm.nih.gov/pubmed/17306350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2007.01.019
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi